Skip to main content

Table 1 Outcome of 15 SAA patients who received the PB+BM transplantation

From: HLA-matched sibling transplantation with G-CSF mobilized PBSCs and BM decreases GVHD in adult patients with severe aplastic anemia

No.

Disease

Conditioning Regimen

GVHD Prophylaxis

Cell number

Engraftment (days)

    
    

NC × 108/kg

CD34 × 106/kg

ANC

PLt

    
    

PB/BM

PB/BM

> 0.5 × 109/L

> 20 × 109/L

> 50 × 109/L

Acute GVHD

chronic GVHD

Survival (Month)

Cause of death

1

VSAA-I

CY/ALG

CsA+MMF

5.95/3.06

3.07/0.89

11

15

18

N

skin

80+

 

2

VSAA-I

CY/ALG

CsA+MMF

2.47/1.9

2.39/0.7

11

14

18

N

N

62+

 

3

SAA-II

CY/ALG

CsA+MMF

2.91/2.6

2.33/1.48

15

47

53

  

7

Late graft

         

N

N

 

Rejection

4

VSAA-I

CY/ALG

CsA+MMF

2.46/2.21

5.66/0.95

14

22

34

N

N

54+

 

5

SAA-I

CY/ALG

CsA+MMF

6.47/1.88

5.3/0.47

10

20

50

N

N

9

Infection

6

SAA-I

CY/ALG

CsA+MMF

4.54/3.87

2.81/1.1

12

20

32

N

N

46+

 

7

VSAA-I

CY/ALG

CsA+MMF

6.17/1.0

1.54/0.3

14

30

35

N

N

30+

 

8

SAA-I

CY/ALG

CsA+MMF

4.64/1.86

4.45/0.71

11

15

18

N

N

30+

 

9

SAA-II

Flu/CY/ALG

CsA+MMF

5.05/1.14

1.36/0.33

12

17

20

N

N

29+

 

10

SAA-II

Flu/CY/ALG

CsA+MMF

3.75/1.47

4.2/0.66

12

15

16

N

N

28+

 

11

SAA-I

CY/ALG

CsA+MMF

2.98/1.77

6.62/0.9

10

15

20

N

N

26+

 

12

VSAA-I

CY/ALG

CsA+MMF

7.80/2.6

5.7/0.85

12

14

15

N

N

26+

 

13

SAA-II

Flu/CY/ALG

CsA+MMF

5.86/2.1

5.03/0.92

13

16

16

N

N

20+

 

14

VSAA-I

CY/ALG

CsA+MMF

2.15/1.9

0.49/1.14

23

27

35

N

N

5

Infection

15

SAA-I

CY/ALG

CsA+MMF

8.3/0.77

1.66/0.17

16

29

48

N

N

7+

 

Median (range)

  

4.64(2.15-8.3)/1.9(0.77-3.87) × 108/kg

3.07(0.49-6.62)/0.85(0.17-1.48) × 106/kg

Day 12 (10-23)

Day 16.5 (14-47)

Day 20 (15-53)

  

Month 27 (7-80)

 
  1. CY: cyclophosphamide; ALG: antihuman T-lymphocyte globulin; MMF: mycophenolate mofetil; CsA: cyclosporine A; N: without any acute GVHD or chronic GVHD